Hepatitis C virus (HCV) is responsible for the majority of No experience has been reported to date in treating cases of post-transfusion non-A non-B (NANB) hepatitis.
Summary:
Hepatitis C virus (HCV) is responsible for the majority of No experience has been reported to date in treating cases of post-transfusion non-A non-B (NANB) hepatitis.
chronic hepatitis C virus (HCV) infection with inter-
We have previously reported a high prevalence of feron (IFN) therapy after BMT, mainly due to concerns chronic hepatitis C virus infection in ␤-thalassemia patients related to the impact of an immunomodulatory drug in who are candidates for BMT. 1 HCV infection has also been patients who are immunologic and haematologic chimreported not to influence transplant outcome and indeed eras. However, chronic inflammatory activity related to HCV infection results in a chronic fibrogenous mechdoes not constitute a contraindication for bone marrow anism potentially leading to liver cirrhosis and hepatotransplant. [1] [2] [3] In immunocompetent patients, persistent cellular carcinoma. Moreover, patients transplanted for HCV infection is associated with the development of ␤-thalassemia could be at greater risk because of conchronic hepatitis, cirrhosis, and hepatocellular carcinoma. on the expression and evolution of HCV-related liver dishistological and molecular biological evidence of HCV ease remains unclear.
5,6
infection were included in the study and treated for 6-IFN therapy has been shown to be effective in the nor-12 months with recombinant IFN 24-65 months followmalization of serum transaminase levels, with improvement ing BMT. The serum alanine aminotransferase (ALT) in the histological activity of hepatitis, and in the clearing was persistently elevated (range 85-1242 U/l; mean 416) of HCV-RNA from serum in immunocompetent patients for at least 1 year prior to IFN treatment. Ten patients with chronic hepatitis C.
7-9
completed the protocol; five were considered as Nothing is known about the efficacy, safety and tolerresponders to treatment. In these five patients the liver ability of this drug in treating chronic HCV infection after histology showed an overall reduction of inflammation BMT, even though some preliminary reports have appeared and necrosis: histological inflammatory activity in organ transplant literature. 10,11 A major concern for the improved from chronic active hepatitis (CAH) to use of IFN in BMT recipients is the risk of inducing or chronic persistent hepatitis (three patients) or minimal precipitating GVHD 12 or allograft rejection, which could residual inflammatory activity (two patients). The be related to the induction of class II histocompatibility Knodell total activity score varied from 5.4 (range 3-antigen expression. 13 That IFN has been occasionally sus-9) to 1.4 (range 1-2; P = 0.05). All responding patients pected in precipitating renal and bone marrow allograft revealed negativization of serum HCV-RNA, that has rejection among patients shortly after transplantation also been persistent in four (follow-up 1-3 years). ALT level adds to the reluctance in using IFN in these patients. 14, 15 fell to 15-80 U/l (mean 52; P = 0.0027). No major comHowever, IFN has already a well established and interplications occurred during the therapy and no influence esting role in the early phase after BMT to prevent or treat on marrow engraftment parameters were noted. We post-transplant recurrent malignancy. 16, 17 conclude that IFN therapy does not adversely interfere In the group of patients reported, in view of the evidence with engraftment and that it is a feasible therapy for of severe liver inflammatory activity, the risk of developing treatment of chronic hepatitis C virus after BMT.
cirrhosis and liver failure within the next few years was, Keywords: interferon; HCV; thalassemia; BMT in our opinion, too high to deny them the possible benefits of therapy. IFN therapy for chronic HCV infection was therefore adopted in an open pilot trial for thalassemiamajor patients 24-65 months (mean 40) post-transplant.
Patients and methods muscle antibody, anti-mitochondrial antibody, anti-gastric parietal cell antibody and anti-nuclear factor), serum immunoglobulins and lymphocyte subsets.
Criteria for eligibility
Serum HCV was assessed by the second-third generation Eleven patients were included in the study. Ten patients enzyme-linked immunosorbent assay (ELISA; Ortho Diag-(four males, six females) tolerated the treatment and comnostic, Raritan, NJ, USA). Serum HCV-RNA was tested pleted the protocol. Ages ranged from 10 to 20 years using the PCR technique with the Amplicor Hepatitis C (mean 14.5).
virus (HCV) test (Hoffmann-LaRoche, Basel, Switzerland), All patients had been regularly transfused pre-transplant, which can detect as few as 1000 copies of HCV-RNA per with the transfusion load ranging from 70 to 404 (mean ml of sample. 188) units of blood. Four patients had undergone splenectomy; all had received desferrioxamine before transplant;
Exclusion criteria however, a variable degree of liver iron load was documented. Liver fibrosis was also present in various degrees
The presence of one of the following conditions was conof severity in all patients ( Table 1 ). The conditioning regisidered as a criterion for excluding the patient from the men for BMT included BU 14 mg/kg and CY 120-200 protocol: (1) time after transplant Ͻ2 years; (2) documg/kg. All patients were negative for antibody to human mentation of mixed chimerism with residual host cells on immunodeficiency virus (HIV) and for hepatitis B antigen, bone marrow (studied by DNA analysis of restriction fragalthough two patients were positive for hepatitis B core ment length polymorphism of variable number tandem antibody. Eight patients were anti-HBs positive as a result repeats (RFLP-VNTR) and, for sex-mismatched pairs, with of HBV vaccination. All patients were HCV-Ab and HCVfluorescence in situ hybridization (FISH) for the Y RNA positive in the serum and had mild (two patients), chromosome); (3) the presence of active chronic GVHD; moderate (four patients) or severe (two patients) chronic (4) concomitant immunosuppressive therapy (cyclosporine, active hepatitis (CAH) or active post-hepatitic cirrhosis azathioprine, steroids, etc); and (5) the presence of hyper-(two patients) on liver biopsy. The serum ALT was persistgammaglobulinemia or autoantibodies. ently elevated (range 85-1242 U/l; mean 416; median 207) in all patients for at least 1 year prior to IFN treatment.
Study protocol Using standard methods the following investigations were carried out during the study period: serum ferritin, Informed consent was obtained from patients following full liver function tests, oral glucose tolerance test, virology disclosure of potential risks and benefits of IFN therapy. status (hepatitis B and HIV serology, anti-HCV, antiRecombinant ␣IFN 3 million units (MU)/m 2 adminis-CMV), thyroid function (serum T4, TSH) and immunologtered by subcutaneous injection three times a week was ical tests (autoantibodies, rheumatoid factor, anti-smooth given to all patients. Blood count, renal function, and serum level of liver enzymes were monitored at 1-2 weeks intervals. Therapy was continued for 6-12 months. Dry weight iron content was measured using a modifi-
The normal reference range for alanine aminotransferase is 2 to 41 U/l; cation of the method originally described by Barry and for serum ferritin 20-300 ng/ml; for liver iron concentration Ͻ1 mg/g of dry tissue.
Sherloch. 20 Response criteria of therapy (from mild CAH to CPH), revealed an additional decrease of necro-inflammatory activity at the following Histologic improvement was defined as a decrease of at histologic check-up (ie minimal inflammatory activity). least one point in the score for necroinflammatory activity
The non-responding patients had no changes in the nec-(see below) when the final result constituted a score not roinflammatory score (one patient with moderate CAH) or higher than 2 (ie MIA or CPH). minimal changes (one patient improved from severe to mild A pre-treatment liver biopsy was compared to a biopsy CAH and one patient from moderate to mild CAH). This performed 12-24 months later. last patient (No. 2 in Figure 1 ) has now substantially Complete response was defined when histologic improved his histologic diagnosis (chronic persistent hepaimprovement was associated with a significant decrease in titis on the last histologic control) while on a phlebotomy serum transaminases (not higher than twice the normal program. value, ie Ͻ82 U/l) and clearance of serum HCV-RNA (at Fibrosis or cirrhosis scores did not differ significantly. least two negative results at 6 months to 1 year interval).
The two patients with a pre-treatment diagnosis of cirComplete normalization of serum transaminases was not rhosis did not respond to treatment, maintaining the HCVjudged to be a criterion because of the concomitant variable RNA positivity and revealing no substantial changes in degree of iron overload that was present in all treated serum transaminases. patients.
Four of the responders and three non-responders received All data are reported as mean values (range), unless additional one to two follow-up liver biopsies at 1 year otherwise specified. Statistical comparisons were made utilintervals (results shown in Figure 1 ). izing the Wilcoxon test for paired data and Mann-Whitney
The semiquantitative (Knodell) scores for histological U test. The level of statistical significance (P) was set at activity and fibrosis are given in Table 2 . Individual compo-0.05.
nents of the histological inflammatory activity scores were comparable in the responders and non-responders. The fibrosis score was lower in responders than in nonResults responders (1.6 vs 3.0), although this was not statistically significant. One patient discontinued IFN at 3 weeks because of persist-
The histology score showed an overall improvement in ent fever and myalgia. responding patients. There was a significant improvement Among 10 subjects completing the protocol, five reached in periportal/bridging necrosis (I)), total activity score (I + the criteria established for a complete response at the end II + III) and total score (I + II + III + IV) between preof therapy.
and post-therapy biopsies (P = 0.05 for each). Intralobular Liver histology showed an overall reduction of inflamdegeneration (II) and portal inflammation (III) did not show mation and necrosis in responding patients: from chronic a statistically significant decrease; fibrosis (IV) showed active hepatitis (CAH) to chronic persistent hepatitis (three only a minimal change. In contrast, no significant changes patients) or minimal inflammatory activity (two patients) have been observed in non-responding patients in any of ( Figure 1 and Table 2) . the parameters considered (Table 2) . Despite the established histologic criteria for response, Anti-HCV tests remained positive after IFN therapy in two patients revealed a decrease of two points in the score all subjects throughout the study. The results of HCV-PCR for necroinflammatory activity at the end of the therapy and testing are given in Table 3 . All responding patients two a decrease of three points. The last responder (No. 4 developed a negative serum HCV-RNA (at least two conin Figure 1 ), who had a decrease of one point at the end secutive results at 6 months to 1 year intervals), which has persisted in four patients. One patient (No. 1 in Table 3 ) became positive for HCV-RNA test after two consecutive negative results, more than 2 years after interrupting IFN therapy. The histologic finding at the same time remained unchanged (chronic persistent hepatitis).
The patients who responded to interferon had an ALT value before treatment ranging from 122 to 1242 U/l (mean 562; median 469), as compared with 85 to 833 (mean 270; median 85) among those who did not respond.
Serum ALT levels improved in all except one patient treated at the end of the therapy.
In the five responding patients the ALT fell to 15-80 U/l (one patient). No reduction in RBC, WBC or platelet count was noted during treatment, necessitating dosage reduction or discontinuation of therapy.
Discussion
The most important observation from this pilot study is that IFN therapy for chronic C viral hepatitis in BMT recipients was safe, effective and well tolerated. In particular, no adverse effects on engraftment or GVHD were observed.
The second point is that this is a pediatric patient population, which is not the case in the majority of published works, where IFN therapy was used in adults.
A third point is that all patients reported in the present study had some other evidence of liver damage, ie some degree of iron overload and fibrosis, as a consequence of pre-existing fibrous liver damage, have been reported to have a synergistic effect with chronic HCV infection in of complete iron removal therapy is ongoing, which may give important indications for future extensive clinical use. accelerating liver damage. 21 As a result of these noxious situations, a chronic transaminase alteration is frequent in
The data reported, however, may be of interest also for non-iron loaded hematology patients with chronic HCV these patients, even in the absence of HBV/HCV chronic infection. 1 infection after BMT. The multifactorial immunomodulatory and antiviral activity of IFN and the peculiarity of 'chimThat patients with idiopathic hemochromatosis can have liver cirrhosis at diagnosis without any contribution from eric' patients after allogeneic BMT suggest a need strictly to maintain the limitations and exclusion criteria already viral hepatitis also highlights the importance of the iron alone as a potent noxious and fibrogenous agent. 22 adopted for further studies. The influence of iron overload on the response to IFN␣ treatment has also been reported in several studies, both in normal and in transfusion-dependent thalassemic popuAcknowledgements lation. [23] [24] [25] However, it is not clear if a cut-off value for liver iron burden that would predict a possible response to
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LIC Ͼ1.1 mg/g predicted a non-response in 88% of patients. The results of this study appear not readily comparable with several reports of IFN therapy in transfusiondependent thalassemia patients in whom the LIC normally References exceeds up to 30 times the value of 1 mg/g. [25] [26] [27] In our patients, we failed to demonstrate a relationship between
